A case report Linezolid induced hematemesis,a rare and life threatening adverse reaction. A case report of Karonga district in Malawi

Samson Chitsulo (1) , David Omotayo (2) , Kuzani Mbendera (3) , Frank Watson Sinyiza (4) , Master Chisale (5) , Balwani Chingatichifwe Mbakaya (6)
(1) a:1:{s:5:"en_US";s:18:"Ministry of health";} , Malawi
(2) Malawi National TB and Leprosy elimination program , Malawi
(3) Malawi National TB and Leprosy elimination program , Malawi
(4) Mzuzu central hospital,malawi , Malawi
(5) Mzuzu university-Malawi , Malawi
(6) Mzuzu university-Malawi , Malawi

Abstract

Background: In 2018,Malawi adopted use of linezolid as for treatment of Multi Drug Resistant Tuberculosis(MDR-TB).Published adverse event reports lack adequate information regarding hematemesis after iniation of linezolid.This case is reported to create awareness among health workers of a rare life threatening adverse effect of linezolid.


Case presentation:A case of an 81 years old male MDR TB patient who developed hematemesis 8 weeks after iniation of linezolid based therapy which resolved after stopping linezolid.He finished other medication at 18 months and declared cured with negative monthly culture results.


Conclusion:The relationship between linezolid and the onset of hematemesis is plausible.Health workers should be alert to the possibility of such adverse reaction.The case has been reported to Malawi National Tuberculosis and Leprosy elimination program(NTLEP).


 

Full text article

Generated from XML file

Authors

Samson Chitsulo
asamchitsulo@gmail.com (Primary Contact)
David Omotayo
Kuzani Mbendera
Frank Watson Sinyiza
Master Chisale
Balwani Chingatichifwe Mbakaya
Chitsulo, S., Omotayo, D., Mbendera, K., Sinyiza, F. W., Chisale, M., & Mbakaya, B. C. (2024). A case report Linezolid induced hematemesis,a rare and life threatening adverse reaction.: A case report of Karonga district in Malawi. Journal of Medical Case Reports and Reviews, 7(5). Retrieved from http://jmcrr.info/index.php/jmcrr/article/view/227
Copyright and license info is not available

Article Details